News stories about ABIOMED (NASDAQ:ABMD) have trended somewhat positive on Thursday, according to Accern Sentiment. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ABIOMED earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 44.4295029977689 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the headlines that may have impacted Accern’s rankings:
- Unsealed Abiomed whistleblower suit reveals claims of retaliation (massdevice.com)
- ABIOMED (ABMD) Banks on Impella Platform, Competition Rife (finance.yahoo.com)
- Analysts Anticipate ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $163.84 Million (americanbankingnews.com)
- Is It Too Late To Buy ABIOMED Inc (NASDAQ:ABMD)? (finance.yahoo.com)
- Zimmer Biomet prices $750m in offerings (massdevice.com)
Several research analysts have recently commented on the stock. BidaskClub lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Jefferies Group raised their price objective on shares of ABIOMED to $250.00 and gave the company a “buy” rating in a research note on Friday, January 12th. SunTrust Banks reaffirmed a “buy” rating and issued a $370.00 target price on shares of ABIOMED in a report on Friday, February 16th. Leerink Swann raised their target price on shares of ABIOMED to $300.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, Morgan Stanley raised their price objective on shares of ABIOMED from $204.00 to $259.00 and gave the stock an “equal weight” rating in a report on Friday, February 2nd. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $288.86.
ABIOMED (NASDAQ:ABMD) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.50 by $0.20. The company had revenue of $154.00 million for the quarter, compared to analyst estimates of $154.00 million. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The business’s revenue was up 34.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.34 EPS. equities analysts forecast that ABIOMED will post 2.3 EPS for the current year.
In other news, VP Andrew J. Greenfield sold 20,000 shares of ABIOMED stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $270.36, for a total transaction of $5,407,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://baseballnewssource.com/2018/03/15/abiomed-abmd-getting-somewhat-favorable-news-coverage-study-shows/1983860.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.